久光制药计划29亿美元买断私有化

生产沙隆巴斯止痛贴的久光制药宣布进行4570亿日元(29亿美元)管理层买断以私有化,这预示着日本药企类似交易浪潮。股价飙升19%,创47年来最大涨幅。此举旨在应对短期投资者审查和政府强制降价,从而获得更大灵活性。

久光制药于1月7日宣布,通过由创始家族成员、首席执行官Kazuhide Nakatomi控制的实体主导的管理层买断实现私有化。该交易价值约4570亿日元(29亿美元),每股要约收购价为6082日元,较周一未受影响收盘价溢价约35%。 公告前一天,股价在彭博社报道潜在交易后上涨16%。公告当天,股价触及当日涨停,收涨19%——创1978年8月以来最大单日涨幅。要约收购期为1月7日至2月19日,资金将来自三井住友银行和三菱UFJ金融集团的贷款。 此事体现了日本药企更广泛地脱离公开市场的趋势。面对短期投资者审查和政府强制降价的双重压力,企业通过退市获得管理灵活性,以实施成本削减、调整产品组合并进行长期投资。过去两年,三菱田边制药和大正制药控股也已私有化。激进投资者道尔顿投资敦促阿斯卡制药控股考虑类似举措。 分析师预计,久光制药的举措将引发更多买断交易,或加速该行业变革。

相关文章

Dramatic scene of panicked traders on Tokyo Stock Exchange floor amid Nikkei plunge and oil surge from Iran conflict.
AI 生成的图像

Oil surge from Iran conflict drives Japanese stocks down

由 AI 报道 AI 生成的图像

Tokyo stocks plunged on March 9, 2026, as surging oil prices fueled by escalating Middle East tensions rattled investors. The Nikkei 225 average fell 5.2% to close at 52,728.72, after dipping as much as 7.6% intraday. Fears of inflation and economic slowdown intensified amid the U.S.-Israeli conflict with Iran.

Major Japanese auto parts maker Denso Corp has withdrawn its buyout proposal for semiconductor firm Rohm Co after failing to secure its support. Denso President Shinnosuke Hayashi announced the decision at a press conference in Nagoya. The company plans to further advance its current relationship with Rohm.

由 AI 报道

Sun Pharmaceutical Industries' shares surged more than 9% following the announcement of its $11.75 billion acquisition of US-based Organon & Co. The deal targets bolstering the Indian company's innovative medicines and positioning it strongly in biosimilars and women's health markets. Organon is recognized as a global leader in women's health.

Japan's Nikkei share average briefly topped 60,000 on Thursday before profit-taking reversed the gains, closing 0.75% lower at 59,140.23 after hitting a record high of 60,013.98. Geopolitical uncertainties in the Middle East weighed on sentiment amid rising oil prices. U.S. President Donald Trump's announcement extending the ceasefire with Iran supported early rises, though Iranian officials rejected any agreement.

由 AI 报道

Boston-based Bain Capital has successfully closed a $12.5 billion fund targeting Asia and Japan. This achievement reinforces the firm's dominant position in the region. The development comes as global investors become increasingly selective.

此网站使用 cookie

我们使用 cookie 进行分析以改进我们的网站。阅读我们的 隐私政策 以获取更多信息。
拒绝